Model Companies Enter Biopharma: 2026, a Pivotal Year for AI Drug Discovery

In 2026, AI drug discovery moves from concept to reality: Insilico Medicine's Rentoserib, a new drug for idiopathic pulmonary fibrosis, has completed first-patient dosing in Phase III, with both target and molecule designed entirely by AI, and topline data expected in 2029; according to Arterial Network, of 117 AI drug pipelines that have entered human clinical trials, only 3 have reached Phase III.